VKTX Viking Therapeutics Inc.

8.36
-0.28  -3%
Previous Close 8.64
Open 8.59
Price To Book 2.04
Market Cap 602318413
Shares 72,047,657
Volume 1,176,800
Short Ratio
Av. Daily Volume 3,323,421

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial to be initiated 2H 2019.
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 trial met endpoints - November 28, 2017. Data at ASBMR September 30, 2018.
VK5211
Acute Hip Fracture

Latest News

  1. 3 Small-Cap Biotech Stocks You Can Buy Right Now
  2. Have Insiders Been Buying Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
  3. Were Hedge Funds Right About Dumping Viking Therapeutics, Inc. (VKTX) ?
  4. Edited Transcript of VKTX earnings conference call or presentation 2-May-19 8:30pm GMT
  5. 3 Top Biotech Stocks to Buy in May
  6. VKTX: Pre-IND Meeting with FDA in Summer 2019; Phase 2b NASH Trial to Initiate 2H19…
  7. Viking Therapeutics Inc (VKTX) Q1 2019 Earnings Call Transcript
  8. Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
  9. Viking Therapeutics to Participate in Upcoming Investor Conferences
  10. 2 Reasons Gilead Sciences' NASH Program Could Bounce Back
  11. Viking Therapeutics to Report Financial Results for First Quarter 2019 on May 2, 2019
  12. VKTX or ENTA: What to Expect from Revenue Growth in 2019
  13. What Are Analysts Recommending for VKTX and ENTA?
  14. VKTX: VK2809 5 mg Data Presented at EASL…
  15. Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
  16. Why Viking Therapeutics Stock Perked Up in March
  17. Here's Why Investors Are Betting Against These 2 Biotech Stocks
  18. Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress™ 2019
  19. 3 Top Value Stocks to Buy Right Now